Total funding reaches $232M under new leadership with investor group comprised of Electronic Arts, Sony Music Group, Universal Music Group, Warner Music Group, and more

LOS ANGELES, Aug. 25, 2026 — Stability AI, the leader in purpose-built AI products for professional creatives across music, gaming, and entertainment, today announced a Series B fundraise of $76M in new capital. The news brings total funding to $232M, inclusive of two equity rounds and convertible notes, under CEO Prem Akkaraju since his appointment in June 2024. The capital will fuel the development of its product suite for creative production, deepen its applied research discipline, and expand its professional services arm.

The round welcomes a new group of investors across entertainment and technology, including interactive entertainment innovator Electronic Arts, global leaders in music entertainment Sony Music Group, Universal Music Group and Warner Music Group, and investment firms AMD Ventures and Pacific Alliance Ventures.

They join an already stacked roster of the who’s who across the entertainment and technology industries backing Stability AI: Coatue, Greycroft, Kadmos Capital, Lightspeed Venture Partners, Mantis Capital, Sound Ventures, and WPP, alongside individual investors Sean Parker, Eric Schmidt, James Cameron, Kevin Mayer, Mark Burnett, Patrick Whitesell, Prem Akkaraju, and Robert Nelsen.

Coatue, Greycroft, Kadmos Capital, Sean Parker, and Eric Schmidt are also participating in the Series B, investing for a second consecutive round under new leadership.

“This unmatched group of investors is an affirmation of our vision where generative AI empowers every producer, musician, and storyteller,” said Prem Akkaraju, CEO of Stability AI. “Stability is unique in the AI field because we are creative people making tools for creatives. Developing industry-defining technology means assembling a team of industry-defining titans, and that’s what we have done here.” Akkaraju added, “Our investors set us up for long-term success because they provide not only capital, but expertise, credibility, and direct connection to artists.”

This round includes investments from existing strategic partners Electronic Arts, Universal Music Group, and Warner Music Group. WPP, a global leader in marketing services, has been a strategic partner and investor throughout Stability AI’s growth under new leadership.

The announcement comes on the heels of the launch of Stable Audio 3.0, a family of open-weight music models trained on fully licensed data. Artists can now bring Stable Audio 3.0 into their workflow through a new DAW (Digital Audio Workstation) plugin or directly on StableAudio.com.

Additionally, Stability AI has announced that Coatue Co-Founder Thomas Laffont has joined its Board of Directors.

“While others are building generalized AI, Stability AI is building creative tools and doing it alongside the artists, studios, and rights holders whose work defines the field,” said Thomas Laffont, Co-Founder of Coatue. “I’m glad to be joining Prem and the team.”

Laffont rounds out a board that includes Academy Award-winning filmmaker James Cameron, entrepreneur, philanthropist, and former President of Facebook Sean Parker, Greycroft Co-Founder and Managing Partner Dana Settle, and Stability AI CEO and former CEO of Weta Digital Prem Akkaraju. With this new funding, Stability AI will continue to build creative tools designed around the artist’s process, across music, gaming, and entertainment.

About Stability AI

Stability AI is the leader in purpose-built AI products for professional creatives across music, gaming, and entertainment.

Stability AI sparked the generative AI revolution with the release of Stable Diffusion in August 2022, putting generative technology in the hands of millions of creators globally and cementing its position as a leader in the field. Stable Diffusion models have since been downloaded more than 350 million times, serving as the technical foundation for an entire ecosystem of work.

We build for creatives first. Our work expands beyond the models themselves into products and solutions designed for specific production workflows. This artist-centric approach is why Electronic Arts, Universal Music Group, Warner Music Group, WPP, and others have chosen us as their strategic partner.

Stability AI is recognized among Fortune’s 50 AI Innovators and TIME’s Most Influential Companies, with Stable Audio named to TIME’s Best Inventions list. In June 2024, Stability AI entered a new phase of growth with a leadership team that included CEO Prem Akkaraju, Executive Chairman Sean Parker, and Board Member James Cameron, as well as board members Dana Settle and Thomas Laffont.

The company is backed by world-class investors including interactive entertainment innovator Electronic Arts; global leaders in music entertainment Sony Music Group, Universal Music Group, and Warner Music Group; investment firms Greycroft, Coatue, WPP, Lightspeed Venture Partners, Sound Ventures, AMD Ventures, and Mantis Capital; and individual investors Sean Parker, Eric Schmidt, and James Cameron.

You can learn more at stability.ai.

Media Contact:
[email protected] 

DUBAI, UAE, Aug. 25, 2026 — Mantle, the open financial network connecting global market participants to institutional-grade capital market assets on-chain, today announced the expansion of Mantle Vault into decentralised finance, built with Grove infrastructure, CIAN, and accessible through Fluxion. The launch extends Mantle Vault beyond its existing centralised finance footprint on Bybit, where it has already crossed $200 million in assets under management, into a new deposit-and-earn product open to any stablecoin holder.

From CeFi to DeFi: Mantle Vault Opens to All

The expansion follows Mantle’s continued momentum in real-world assets, with RWA TVL growing from $22 million to $257 million in a year and DeFi TVL exceeding $755 million. This marks the next stage of Mantle’s thesis that institutional-grade assets should be reachable by any market participant, not only the institutions and exchanges that first brought them on-chain.

The expanded Mantle Vault allows users to deposit $USDC and $USDT0 on Mantle to access variable yield generated by the underlying strategy. The strategy includes exposure to sUSDS, Sky Protocol’s yield-bearing token, alongside Fluxion Points. Built by CIAN in coordination with Grove, the vault follows a conservative, non-leveraged structure with transparency into the underlying strategy.

Mantle is also introducing a dedicated incentive programme of 5.14 million GROVE tokens, targeting up to 6.5% APY. Programme terms, duration and rates may vary based on market conditions, and incentives are not guaranteed.

“Mantle Vault started as a product built for Bybit’s user base. Its expansion into DeFi through Grove, CIAN, and Fluxion shows what an open financial network is meant to do: connect global market participants to institutional-grade capital market assets, wherever they are,” said Emily Bao, Key Advisor at Mantle and Spot Executive at Bybit.

Grove: Bringing Institutional Grade Economy onto Mantle

Within Mantle Vault, Grove provides the capital foundation through Grove Savings, the on-chain interface to the Sky Savings Rate. The Sky Savings Rate is set by Sky governance and delivered by the Sky Agent Network, an independent network of capital allocators competing across diversified, governance-approved yield strategies through Sky Protocol.

“We’re happy to bring Grove to Mantle. Grove supports the ecosystem by bringing Grove Savings, the on-chain interface to the Sky Savings Rate, a rate set by Sky governance. Partners like Mantle, CIAN, and Fluxion help make institutional-grade on-chain strategies accessible to more users.” said Kevin Chan, Co-Founder of Grove. 

CIAN: Translating Institutional Portfolio Construction into a Non-Custodial Product

CIAN built the original Mantle Vault on Bybit. That track record now extends into DeFi, with CIAN translating institutional-grade portfolio construction into a single, non-custodial product on top of the sUSDS exposure provided by Grove.

“At CIAN, we translate institutional-grade portfolio construction into transparent, non-custodial yield infrastructure. Together with Grove, Mantle, and Fluxion, we are making capital-preservation-first strategies easier for stablecoin holders to access,” said Luffy, Founder of CIAN.

Fluxion: The Liquidity Layer for Stablecoin Holders on Mantle

Fluxion provides the liquidity layer for the expanded Mantle Vault, giving stablecoin holders on Mantle access to the product and connecting deposits to Fluxion Points as an added benefit.

As the Mantle-native DEX for RWA distribution, Fluxion combines hybrid AMM/RFQ trading with xStocks’ xChange, giving users direct access to tokenized equity trading and supporting liquidity across Mantle’s RWA ecosystem.

Fluxion previously expanded its Earn offering with RWAIpha and now adds Mantle Vault to the lineup, giving users access not only to RWA token trading but also to the underlying infrastructure supporting these assets.

“Partnering with Grove and CIAN to introduce a stablecoin vault on Mantle marks a strong start for our Earn product. Together, we look forward to making Mantle the leading hub for real-world assets,” said Sham, CMO at Fluxion.

Borderless Access to Institutional-Grade Yield

The expansion of Mantle Vault from CeFi into DeFi  brings together four organisations around a single objective: making institutional-grade yield accessible to any stablecoin holder, without geographic restrictions or intermediary gatekeeping. Grove provides the capital foundation, CIAN the yield infrastructure, and Fluxion the liquidity layer, each composable within Mantle’s open financial network. As Mantle continues to expand the range of institutional-grade assets and strategies accessible on-chain, Mantle Vault represents the clearest demonstration yet of what an open financial network is built to deliver.

About Mantle

Mantle is the open financial network powering borderless access to global capital markets, connecting global market participants to institutional-grade capital market assets on-chain. Mantle brings the full lifecycle of real-world assets on-chain, from issuance and liquidity to distribution and settlement, spanning tokenized equities, treasury yield, private credit, commodities, and money markets. Anchored by one of the largest community-owned treasuries in the industry, Mantle combines credibility, deep liquidity, and institutional-grade infrastructure to support real-world finance on-chain.

For more information visit mantle.xyz.
For more social updates, please follow: Mantle Official X & Mantle Community Channel

About Grove

Grove is capitalizing the stablecoin economy. Through institutional-grade allocation, financing, and liquidity, Grove brings real-world assets and real-world use cases onchain to help build the next generation of global financial markets. Grove’s flagship product, Basin, is programmable credit infrastructure designed to provide eligible investors with real-time stablecoin liquidity in connection with approved sale, redemption, transfer, or other liquidity transactions for tokenized real-world assets. Grove is issuer-agnostic, product-conflict-free, and designed to serve as a neutral infrastructure layer for the tokenized asset ecosystem.

To learn more, visit grove.finance, X, and LinkedIn.

About Cian

CIAN Yield Layer is a leading on-chain yield strategy platform, offering users one-click access to advanced strategies while driving sustainable growth for emerging assets—both crypto-native and real-world —by generating extra on-chain yield for holders.

Standing at $1.4B in TVL, CIAN collaborates with top-tier protocols—including Mantle, Lido, Binance, Maple, USD1, Superstate, Renzo, Kernel, Horizon, pyUSD, cbBTC, fBTC, solvBTC, and Bedrock, etc. — to fuel asset growth. Beyond crypto-native assets, CIAN is expanding access to institutional-grade, interest-bearing RWAs issued by leading Wall Street and London institutions, partnering with RWA pioneers like Chainlink, Midas etc., which effectively bridges the gap between DeFi and TradFi.

For more information about CIAN, please visit: Cian.app
For documentation, please visit: Docs.Cian.app
For updates, please follow: X CIAN_protocol &DC Cian Discord

About Fluxion

Fluxion is a native DEX which is also a RWA distribution hub on Mantle. Fluxion adopts a hybrid trading model- AMM/RFQ. Now you can buy all xStock assets on Fluxion via RFQ. And for the Fluxion AMM model, users can trade and manage liquidity with a borderless access experience. Until now, accumulated trading volume across 1B+ USD, weekly high is 100M+USD.

Now, trade xStock assets on Fluxion can both earn Fluxion Points and xStock’s xPoints.

Please come to visit: fluxion.network

For more social info: https://x.com/Fluxion_network

For media enquiries, please contact: [email protected]

SOURCE Mantle

Founders Compass awards cover lab bench and office space at Ocean State Labs for 12 months — with the equipment and support to carry a discovery forward

Companies may apply from anywhere in the country. Applications open August 24 and close September 24

PROVIDENCE, R.I., Aug. 25, 2026 — For an early-stage life science company, the hardest part often isn’t the discovery. It’s finding a place to develop it — a lab, the equipment, and the right environment to realize it.

Today the Rhode Island Life Science Hub (RILSH) announced the Founders Compass Program, offered in partnership with Portal Innovations — the first Rhode Island program to pay for laboratory space directly on behalf of early-stage companies to help accelerate them through the early stages of scientific development. It is open to founders and researchers across the United States and beyond.

Founders Compass will place up to eight companies at Ocean State Labs, the state’s first dedicated life science incubator. Each selected company receives up to two wet lab benches and a dedicated desk, at no cost for 12 months. Portal Innovations, which operates the incubator, provides the laboratory infrastructure, equipment, programming, access to capital, a global network of resources, and advisor support behind the residency. RILSH has committed $250,000 to the program to support up to 8 companies and their early-stage research and development.

What Founders Compass provides

• Rent-free lab and office space. Up to two wet lab benches and one dedicated desk at Ocean State Labs, at no cost for 12 months.
• Access to shared facilities and specialized equipment.
• Advisors and community. Advisor support throughout the residency, educational programming, and access to a growing community of founders, scientists, investors, and industry leaders — including Portal Innovations’ network of sites in Chicago, Providence, New Brunswick, and Salt Lake City (opening in 2027).
• Open to founders anywhere. Companies may apply from any state or from abroad; what is required is a commitment to operate in Rhode Island.
• Up to eight companies, selected from a total RILSH commitment of $250,000.

“Early-stage companies need a place to advance their work — access to lab space, specialized equipment, and expertise – resources that are difficult for a young company to build on its own,” said Bob Cormier, President and CEO of the Rhode Island Life Science Hub. “Founders Compass helps lower those barriers so promising companies can focus on advancing their science. Our goal is to make it easier for good science to move forward — and for companies to build their future here in Rhode Island.”

Applications open August 24, 2026 and close September 24, 2026, with awards announced approximately four weeks later. Applications are evaluated against published criteria: scientific and technical merit, commercial potential, team strength, residency readiness, financial readiness, and impact in Rhode Island. Each recipient commits to establish, maintain, or expand its operations in Rhode Island for the term of the award.

Open to founders anywhere

Founders Compass is not limited to companies already based in Rhode Island. Researchers and founders across the United States and internationally are eligible to apply. The requirement is not where a company starts — it is a commitment to establish, maintain, or expand operations in Rhode Island for the term of the award.

That path is already well traveled. RILSH’s portfolio includes companies that have relocated to Rhode Island from California, Connecticut, Massachusetts, and Ireland to build here.

“If you’re a researcher with a discovery and nowhere to develop it, we want you to look at Rhode Island,” Cormier said. “You don’t have to be from here. You have to want to build here.”

The space

Ocean State Labs opened in May 2026 at 150 Richmond Street as Rhode Island’s first dedicated life science incubator, with fully equipped laboratory facilities built for up to 30 companies. It sits in the heart of Providence’s Innovation District, in a building with additional purpose-built laboratory and office space for companies ready to grow beyond the incubator — so a company can start at a single bench, prove its science, and scale without ever changing addresses.

“Access to affordable, ready-to-use lab space can be a significant hurdle for an early-stage life science company,” said Glenn Robertelli, Executive Director of RI Bio. “Founders Compass adds an important resource to Rhode Island’s growing ecosystem by giving companies a place to work, connect with other founders and industry leaders, and establish a foothold here. It gives entrepreneurs another compelling reason to look at Rhode Island as a place to build.”

Take a look at Ocean State Labs drone video fly-through here.

Who is eligible

The program is open to early-stage, for-profit companies working in biotechnology, therapeutics, diagnostics, medical devices, biomanufacturing, genomics, cell and gene therapy, research tools, and other regulated human health technologies. Applicants must have at least one full-time founder or employee, have raised no more than $5 million in dilutive capital, have generated less than $1 million in revenue over the preceding 12 months, conduct work at BSL-1 or BSL-2, and be committed to establishing or expanding operations in Rhode Island.

Applications and full eligibility criteria are available at www.rilifescience.com/founders-compass.

About Ocean State Labs

Ocean State Labs is Rhode Island’s first dedicated life science incubator, located at 150 Richmond Street in the heart of 195 District – Providence’s Innovation District. It is operated by Portal Innovations.

About Portal Innovations

Portal Innovations builds life science ecosystems in emerging biotech markets, providing early-stage capital, fully equipped laboratory space, and operational support to scientists and entrepreneurs turning breakthroughs into businesses. Portal operates five sites — two in Chicago, Providence, New Brunswick, and Salt Lake City (opening in 2027) — comprising more than 110,000 square feet of lab and office space and more than $12 million in laboratory equipment, serving a community of over 500 members. For more information, visit www.portalinnovations.com.

About RI Bio

RI Bio is the professional trade association and hub for the life sciences in the greater Rhode Island area, with a mission to grow the life sciences economy in Rhode Island and Southeastern New England. RI Bio advances the industry and its professionals through education, collaboration, and advocacy — sharing information and resources, providing access to capital, and creating industry connections. For more information, visit www.ri-bio.org.

About the Rhode Island Life Science Hub

The Rhode Island Life Science Hub (RILSH) is a quasi-public state entity working to grow and serve Rhode Island’s life-science community — investing in, coordinating, and connecting academia, industry, clinical care, and capital to translate innovation into economic growth and improved health. Its vision is a Rhode Island recognized as a global life-science leader — a destination where companies from anywhere can build and grow, and where discovery becomes better health for people everywhere. As the state’s central coordinating organization for life sciences, RILSH is a gateway into Rhode Island’s research institutions, health systems, and talent — bringing companies and partners together to advance medical and scientific breakthroughs. For more information, please visit www.rilifescience.com.

Media contact:

RILSH
Sarah Sutton
[email protected]
(518) 932-3580

SOURCE Rhode Island Life Science Hub

Interval fund provides individual investors with access to diversified small and middle market infrastructure investments positioned to benefit from long-term megatrends.

MONUMENT, Colo., Aug. 25, 2026 — As demand grows for infrastructure investments, Advisors Asset Management (AAM) and Wilshire announced the launch of the AAM Wilshire Infrastructure Fund (AAWIX / AAWDX / AAWSX), enabling individual investors to participate in a private asset class that has historically been available primarily to large institutions. Sun Life Financial Inc., a global financial services organization with approximately $1.2 trillion in assets under management, has committed $150 million in seed capital to the Fund.

The AAM Wilshire Infrastructure Fund is designed to provide investors with access to a portfolio of global infrastructure assets positioned to benefit from long-term megatrends including digitalization, transportation, the energy transition, and social infrastructure. The Fund focuses on small- and middle-market opportunities, where specialized sourcing, value creation initiatives, and reduced competition may enhance return potential and diversification benefits.

“Private infrastructure has delivered compelling risk-adjusted returns for institutional investors for decades, yet access within the broader wealth channel has remained limited,” said Cliff Corso, Chief Executive Officer and President of Advisors Asset Management. “The AAM Wilshire Infrastructure Fund helps bridge that gap. Through our partnership with Wilshire, we are providing access to private infrastructure through an interval fund structure designed to meet the needs of individual investors.”

The Fund is sub-advised by Wilshire, a global financial services firm with approximately $1.3 trillion in assets under advisement and $33.2 billion in alternative assets under management.¹ Since 1972, Wilshire has been dedicated to improving investment outcomes for institutional investors and financial intermediaries worldwide, including pension plans, endowments, foundations, and wealth management firms. The firm has built its private markets capabilities in-house since 1984.

“We believe the world is at a pivotal moment, as powerful megatrends drive a significant need for new and upgraded infrastructure,” said Jason Schwarz, Chief Executive Officer of Wilshire. “The AAM Wilshire Infrastructure Fund is designed to capture opportunities arising from these trends. We are excited to bring our decades of private markets expertise to a broader range of investors.”

Through the Fund, investors gain exposure to difficult-to-access infrastructure managers and investment opportunities. Wilshire manages the Fund alongside similar infrastructure mandates for its institutional clients. The Fund invests across infrastructure funds, secondaries, and co-investments, providing diversified exposure across managers, strategies, and underlying assets.

Structured as an evergreen interval fund, the AAM Wilshire Infrastructure Fund is available for daily purchase with a minimum investment of $5,000.² The Fund does not require ongoing capital calls and provides tax reporting through Form 1099 rather than Schedule K-1, offering a streamlined investment experience for individual investors.

About Advisors Asset Management
With roots dating back to 1979, AAM has become a trusted resource for financial professionals. The firm offers access to alternative investments, exchange-traded funds, fixed income markets, managed accounts, mutual funds, structured products, and unit investment trusts. AAM is a part of SLC Management, the alternatives and traditional asset management business of Sun Life. For more information, visit www.aamlive.com.

Advisors Asset Management, Inc. (AAM) is a SEC-registered investment advisor and member FINRA/SIPC. | Registration does not imply a certain level of skill or training. | 18925 Base Camp Road | Monument, CO 80132

For more information, visit www.aamlive.com | LinkedIn: https://www.linkedin.com/company/advisors-asset-management-inc-/ 

About Wilshire
Wilshire is a leading global financial services firm and trusted partner to a diverse range of approximately 300 leading institutional investors and financial intermediaries.³ Our clients rely on us to improve investment outcomes for a better future. Wilshire advises on over $1.3 trillion in assets and manages $183 billion in assets as of March 31, 2026.¹ Wilshire is headquartered in the United States with offices worldwide. The firm has been providing services in the private markets since 1984; these capabilities were and continue to be developed in-house. In 1996, Wilshire created a specialized private markets practice to meet the growing institutional investor appetite for private markets investments. Wilshire’s private markets investment due diligence is led by local teams in North America, Europe and Asia allowing a combined global perspective with local market presence. Wilshire seeks to create high-performing diversified private markets solutions that prudently manage portfolio risk, compensate investors for illiquidity and meet or exceed clients’ risk-adjusted return expectations. More information on Wilshire can be found at www.wilshire.com.

Glossary of Terms

• A co-investment is in an investment, alongside a general partner, in an infrastructure asset or private infrastructure company.
• An evergreen interval fund is a type of closed-end fund that offers investors limited liquidity through scheduled periodic repurchase offers, rather than daily redemptions like a mutual fund.
• Secondaries involve buying existing interests in either Primary Funds from an investor (“LP-led”) or private assets from a General Partner (“GP-led”).
• Small and middle-market infrastructure opportunities include transaction sizes of approximately $100 million to $2 billion, and Portfolio Fund sizes of approximately $500 million to $5 billion.

Additional Important Information

Past performance does not guarantee future results. All amounts are shown in US$.

1. As of 3/31/2026. Assets under advisement refers to the total amount of assets (inclusive of assets under management) attributable to all of Wilshire’s advisory relationships, including various consulting and advisory relationships for which Wilshire provides investment advisory services without engaging, on either a discretionary or non-discretionary basis, in the direct management of a client’s portfolio. Assets under management refers to the amount of assets attributable to securities portfolios for which Wilshire provides discretionary and non-discretionary asset management services and is calculated differently than “regulatory assets under management”.
2. The minimum initial investment for Class S Shares (AAWSX) and Class D Shares (AAWDX) is $5,000, subject to certain exceptions, and minimum subsequent investments are $1,000. The minimum initial investment for Class I Shares (AAWIX) is $1,000,000, and minimum subsequent investments are $1,000.
3. As of 12/31/2025. Includes institutional investors, financial intermediaries, and Wilshire-sponsored vehicles. Does not include individual retirement plans and retail investors via financial intermediary platforms.

Before investing, carefully consider the AAM Wilshire Infrastructure Fund’s (the “Fund”) investment objectives, risk factors, charges, and expenses. This and other information can be found in the Fund’s prospectus, which may be obtained by visiting www.aamlive.com. Investors should read the prospectus carefully before investing.

An investment in the Fund involves risks. The Fund should be considered a speculative investment that entails substantial risks, and a prospective investor should invest in the Fund only if it can sustain a complete loss of its investment. Fund fees and expenses may offset trading profits. Fund shares are illiquid and appropriate only as a long-term investment. There is no market exchange available for shares of the Fund thereby making them difficult to liquidate. Use of leverage may increase the Fund’s volatility. The Fund is non-diversified, meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Investments may consist of loans to small and/or less well-established privately held companies that have reduced access to the capital markets, resulting in diminished capital resources and the ability to withstand financial distress. Please see the prospectus for details of these and other risks.

The Fund is a non-diversified, closed-end investment company that continuously offers its shares. An investment in the Fund should be considered a speculative investment that entails substantial risks, including but not limited to the following:

• You will not have access to the money you invest for an extended period of time
• You will not be able to sell your Shares regardless of how the Fund performs.
• Because you will be unable to sell your Shares, you will be unable to reduce your exposure to Shares upon any market downturn.
• The Fund does not intend to list its Shares on any securities exchange and the Fund does not expect a secondary market in its Shares to develop.
• The Fund has implemented a Share repurchase program, but the Fund is required to repurchase only 5% (and may not repurchase more than 25%) of its outstanding Shares per quarter.
• Shares are appropriate only for those investors who can tolerate a high degree of risk, do not require a liquid investment, and for whom an investment in the Fund does not constitute a complete investment program.
• The amount of distributions that the Fund may pay, if any, is uncertain.
• The Fund’s distributions may be funded from offering proceeds or borrowings, which may constitute a return of capital and reduce the amount of capital available to the Fund for investment. A return of capital to shareholders is a return of a portion of their original investment in the Fund, thereby reducing the tax basis of their investment. As a result of such reduction in tax basis, shareholders may have taxable gains in connection with the sale of Shares, even if such Shares are sold at a loss relative to the shareholder’s original investment.
• Fund distributions may also be funded from the waiver or payment of certain expenses by the Advisor that will be subject to repayment in the future. The repayment of any amounts owed to the Advisor will reduce the future distributions to which you would otherwise be entitled.

Infrastructure companies may be subject to a variety of factors that may adversely affect their business, including economic slowdown, supply and demand volatility, increased competition, fluctuations in usage, expenses, and revenue, lack of fuel availability, energy conservation policies, technological obsolescence and changes in interest rates, regulations, or fiscal and monetary policy. Property values may fall due to increasing vacancies or declining rents resulting from unanticipated economic, legal, cultural or technological developments. There is no regular market for interest in infrastructure assets, which typically must be sold in privately negotiated transactions that can occur at a discount to the stated NAV.

The Fund will allocate a portion of its assets to multiple investment funds, and shareholders will bear two layers of fees and expenses: management fees and administrative expenses at the Fund level, and asset-based management fees, carried interests, incentive allocations or fees and expenses at the Investment Fund level.

A significant portion of the Fund’s investments will likely be priced by investment funds in the absence of a readily available market and may be priced based on determinations of fair value, which may prove to be inaccurate. Please see the prospectus for additional information.

The AAM Wilshire Infrastructure Fund is distributed by Quasar Distributors, LLC. Quasar, Wilshire and AAM are not affiliated.

CRN: 2026-0731-13663 R

CONTACT:

AAM Media Contact:
Matthew Bono
JConnelly
(973) 590-9110
[email protected]

Wilshire Media Contact:
‍Prosek Partners
[email protected]

SOURCE Advisors Asset Management; Wilshire

— Funds will accelerate AI design automation platform and customer projects —

SANTA CLARA, Calif., Aug. 25, 2026 — Celera Semiconductor, the leading analog IC supplier using AI to slash the cost and time to develop and supply analog ICs, today announced it had closed $30M of Series B financing. The round was fully funded by Maverick Silicon, Celera’s largest investor.

“Celera has made significant progress in the last two years,” said Patrick Brockett, CEO of Celera Semiconductor. “We recently acquired Silicon Gate, a world class product development and design automation team in Portugal. We are rapidly expanding that team.”

“We have also enhanced Celera’s design and AI leadership in California, expanding the power management applications we can address,” said Dr. Helen Song, CTO of Celera Semiconductor. “Furthermore, this funding will accelerate our design automation roadmap.”

“Celera is creating a new and highly efficient option to source custom analog designs,” said Kenneth Safar, Managing Director at Maverick Silicon. “Every system has critical analog content, and sourcing those products has created schedule challenges for many customers. Celera is providing a way to remove these barriers. We believe the impact will be substantial.”

About Celera Semiconductor

Celera Semiconductor is redefining the future of analog IC design. Using software acceleration based on its patented Nesto™ technology – the industry’s first library of digital twins of analog functions. Celera Semiconductor is the first to offer full-custom or standard products in a fraction of the time of traditional semiconductor companies. Headquartered in Santa Clara, CA, Celera partners with world-class supply chain players to deliver high-performance, cost-efficient analog solutions at unprecedented speed. Maverick Silicon is the major investor in Celera.

For more information, visit www.celerasemi.com

About Maverick Silicon

Maverick Silicon is an investment adviser focused on private semiconductor growth companies and related opportunities. This includes a focus on companies designing or producing chips, hardware, software or processes that accelerate or enable the performance of the broader infrastructure stack underlying artificial intelligence. Maverick Silicon is a division of Maverick Capital, a global $10B asset manager.

For more information, visit www.mavericksilicon.com/

SOURCE Celera Semiconductor

Global institutional investors join in the round to accelerate tokenization infrastructure build-out and expand frontier tech investing capability

NEW YORK and LONDON, Aug. 25, 2026 — Hivemind Digital Group, a leading technology-focused global asset management platform and the parent company of Hivemind Capital, today announces the completion of a $17 million strategic funding round led by M&G Investments. The round also includes participation from CPIC Investment Management (HK), ZA Bank, FalconX, Sonic Boom Ventures and others.

Founded in 2021, Hivemind has quickly grown into one of the largest investment firms focused on managing assets at the intersection of traditional markets and the digital asset innovation. This funding round accelerates Hivemind’s evolution in deploying tokenization infrastructure that has the potential to reshape elements of how financial assets – both traditional and digital – are structured, managed and accessed.

The investment also marks the beginning of the relationship between Hivemind and M&G, in recognition of the role digital assets and tokenization will increasingly play in the financial markets. As part of the investment, Alex Seddon, Head of Impact and Private Equity at M&G Investments, has been appointed to Hivemind’s Board of Directors.

“Hivemind was founded on the conviction that digital assets deserved recognition as a distinct and institutional-grade asset class. The market has evolved significantly in recent years with increasing institutional engagement. This funding round and our partnership with M&G represent the start of our next chapter: taking blockchain technology beyond digital assets and supporting the development of new applications across asset management and financial infrastructure. M&G leading this round is a huge recognition of the work Hivemind has done to date and a clear signal that the industry is ready for that shift, and we intend to be at the forefront of that change,” said Matt Zhang, Founder and CEO of Hivemind Digital Group.

“At M&G we take a selective approach to innovation, focusing on opportunities where new technologies meet institutional standards and robust governance. Our investment in Hivemind reflects an interest in how tokenization and related infrastructure could support practical, long-term applications across financial markets – we look forward to working together as this area continues to develop, ” said Alex Seddon, Head of Impact and Private Equity at M&G Investments.

“As one of Hong Kong’s leading insurance asset managers as well as a digital asset and RWA frontrunner, CPIC IMHK has a unique vantage point on how capital markets are evolving globally. Blockchain and tokenization represent a fundamental shift in that landscape, and Hivemind is one of the few firms with the track record and institutional relationships to capitalize on that opportunity at scale. We are proud to support Matt and the firm as it enters this next stage of growth,” said CG Zhou, CEO of CPIC IMHK.

Other investors in the round include board members and ex-senior executives at Man Group Plc, Apollo Global Management, Coinbase, Citi, First Citizens Bank and GoldenTree Asset Management.

The tokenized asset market is projected to reach $18.9 trillion by 2033. With this raise, Hivemind is equipped to move decisively: deploying capital into unique opportunities enabled by tokenization across asset classes, expanding its institutional partnerships globally, and building the financial infrastructure enabling the next-generation asset management industry.

About Hivemind Digital Group

Hivemind Capital is a global investment group operating at the intersection of traditional finance and the digital asset innovation. Founded in 2021, Hivemind allocates institutional capital across a diverse set of investment strategies, and implements technology infrastructure to help assets and institutions transition onto blockchain rails with discipline, durability, and scale. Learn more at hivemind.capital.

About M&G Investments

M&G Investments is part of M&G plc, a savings and investments company with £371 billion of assets under management (as at 31 March 2026). M&G plc has customers in the UK, Europe, the Americas and Asia, including individual savers and investors, life insurance policy holders and pension scheme members.

For nearly nine decades M&G Investments has been helping its customers to prosper by putting investments to work, which in turn creates jobs, homes and vital infrastructure in the real economy. Its investment solutions span equities, fixed income, multi asset, cash, private debt, infrastructure and real estate.

M&G plc recognises the importance of responsible investing, is a signatory (both as an asset manager and owner) to the UN-supported Principles for Responsible Investment (PRI), and is targeting net zero emissions by 2050, across our investment portfolios and operations. For more information, please visit: www.mandg.com 

SOURCE Hivemind

• Die Kapitalerhöhung dient der Finanzierung der laufenden klinischen Studie der Phase 2b/3 zur Prävention der bronchopulmonalen Dysplasie sowie der damit verbundenen CMC- und analytischen Aktivitäten
• Rund 94 % der bestehenden Investoren beteiligten sich an der Finanzierungsrunde der Serie E-2
• Eine Zwischenanalyse zum Abschluss des Phase-2b-Teils der Studie wird voraussichtlich bis Ende des 2. Quartals 2027 vorliegen

ATLANTA, 25. August 2026 — Airway Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der späten klinischen Entwicklungsphase, das neuartige biologische Therapien für Atemwegs-, Entzündungs- und Infektionserkrankungen entwickelt, gab heute den Abschluss einer Finanzierungsrunde in Höhe von 50 Millionen US-Dollar bekannt, um die weitere klinische Entwicklung von Zelpultide alfa – dem neuartigen rekombinanten humanen Surfactant-Protein D (rhSP-D) des Unternehmens – in der späten klinischen Phase zu unterstützen.

Die E-Finanzierungsrunde setzt sich aus 26 Millionen US-Dollar zusammen, die zuvor im Rahmen einer SAFE-Finanzierung eingeworben wurden, sowie aus 24 Millionen US-Dollar aus der Serie-E-2-Finanzierungsrunde des Unternehmens. Die Mittel werden in erster Linie dazu dienen, Airway beim Abschluss des laufenden Teils der klinischen Phase-2b/3-Studie zu unterstützen, in der Zelpultide alfa zur Prävention der bronchopulmonalen Dysplasie (BPD) bei extrem frühgeborenen Säuglingen untersucht wird, sowie die damit verbundenen Aktivitäten in den Bereichen Chemie, Herstellung und Kontrollen (CMC) und Analytik zu finanzieren, die für den Fortgang des Programms erforderlich sind.

An der Finanzierungsrunde der Serie E-2 beteiligten sich zahlreiche bestehende Investoren von Airway; rund 94 % der bestehenden Investoren nahmen an der Runde teil. Zu den Teilnehmern zählten das Cincinnati Children’s Hospital sowie ein Konsortium großer Family Offices, die sich für die Weiterentwicklung neuartiger Therapien für schwere Atemwegserkrankungen einsetzen.

„Wir freuen uns außerordentlich über die rege Beteiligung und die anhaltende Unterstützung unserer bestehenden Investoren, wobei sich rund 94 % unserer derzeitigen Kapitaltabelle an der Serie-E-2-Finanzierungsrunde beteiligt haben, was ihr Vertrauen in Airway, unser Team und das Potenzial von Zelpultide alfa widerspiegelt”, sagte Dr. Marc Salzberg, Chairman und Chief Executive Officer von Airway Therapeutics. „Mit dieser Finanzierungsrunde sind wir gut aufgestellt, um die Dynamik in unserem klinischen Programm im Spätstadium aufrechtzuerhalten, während wir Zelpultide alfa zur Prävention von BPD bei extrem frühgeborenen Säuglingen untersuchen – einer Patientengruppe mit erheblichem ungedecktem medizinischem Bedarf und ohne zugelassene präventive Therapien.”

„Diese Finanzierungsrunde festigt die finanzielle Lage von Airway weiter, während wir die laufende klinische Studie der Phasen 2b/3 durchführen und uns auf die nächsten wichtigen Entwicklungsmeilensteine des Programms vorbereiten”, sagte Alan S. Wolk, MBA, Chief Financial Officer und Chief Operating Officer von Airway Therapeutics. „Die Erlöse verschaffen uns das Kapital, um die klinische Studie sowie die für die CMC- und BLA-Vorbereitung erforderlichen analytischen Arbeiten zu finanzieren, die notwendig sind, um Zelpultide alfa auf disziplinierte und effiziente Weise durch die späte Entwicklungsphase zu führen.”

Der nächste wichtige Meilenstein in der Entwicklung von Airway ist die geplante Zwischenanalyse, die den Abschluss des Phase-2b-Teils der laufenden klinischen Phase-2b/3-Studie markiert. Die Ergebnisse der Zwischenanalyse werden voraussichtlich bis Ende des zweiten Quartals 2027 vorliegen.

Informationen zu Zelpultide Alfa
Zelpultide alfa ist ein rekombinantes humanes Surfactant-Protein D (rhSP-D), das präzise so entwickelt wurde, dass es die vollständige quaternäre Struktur und die biologische Funktion des nativen Proteins nachbildet, wobei durch fortschrittliche Zelllinientechnologie eine optimierte Glykosylierung erreicht wurde. Seine therapeutische Wirksamkeit beruht auf drei wesentlichen Mechanismen: der Modulation von Immunreaktionen zur Eindämmung übermäßiger Entzündungen, der Verbesserung der Erkennung und Beseitigung von Krankheitserregern sowie der Aufrechterhaltung der Surfactant-Homöostase zur Unterstützung der Lungenfunktion. Als vielseitige biologische Plattform wird Zelpultide alfa für Patienten aller Altersgruppen entwickelt – von der Prävention der bronchopulmonalen Dysplasie (BPD) bei extrem frühgeborenen Säuglingen bis hin zur Behandlung akuter und chronischer Atemwegs-, Entzündungs- und Infektionserkrankungen bei Erwachsenen.

Die Hauptindikation von Zelpultide alfa, die Prävention der BPD, durchläuft derzeit eine klinische Studie der Phase 2b/3, nachdem eine Phase-1b-Studie ein günstiges Sicherheits- und Verträglichkeitsprofil nachgewiesen hat.

Informationen zu Airway Therapeutics
Airway Therapeutics ist ein biopharmazeutisches Unternehmen in der späten klinischen Entwicklungsphase, das eine neue Klasse biologischer Therapien entwickelt, um die Prävention und Behandlung von Atemwegs-, Entzündungs- und Infektionserkrankungen neu zu definieren. Sein führender Wirkstoffkandidat, Zelpultide alfa, befindet sich derzeit in der späten klinischen Entwicklungsphase zur Prävention der bronchopulmonalen Dysplasie (BPD) bei extrem frühgeborenen Säuglingen – einer Erkrankung, für die es bislang keine zugelassenen präventiven Therapien gibt. Als Plattform-Biologikum wird Zelpultide Alfa zudem für eine breitere Anwendung über verschiedene Altersgruppen und Krankheitsbilder hinweg vorangetrieben, mit dem Ziel, die Behandlungsergebnisse für gefährdete Patientengruppen zu verbessern.

Weitere Informationen finden Sie unter https://www.airwaytherapeutics.com

Unternehmenskontakt:
Libba Muzi
Airway Therapeutics
[email protected]
513-770-9630

• The capital raise supports ongoing Phase 2b/3 clinical trial for prevention of bronchopulmonary dysplasia and associated CMC and analytical activities
• Approximately 94% of existing investors participated in the Series E-2 round
• Interim analysis completing the Phase 2b portion of the trial expected by the end of Q2 2027

ATLANTA, Aug. 25, 2026 — Airway Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced the closing of a $50 million equity round to support the continued late-stage clinical development of zelpultide alfa, the Company’s novel recombinant human surfactant protein D (rhSP-D).

The E-round consists of $26 million previously raised through a SAFE financing and $24 million through the Company’s Series E-2 round. Proceeds will primarily support Airway’s completion of the ongoing Phase 2b portion of the Phase 2b/3 clinical trial evaluating zelpultide alfa for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants, as well as associated chemistry, manufacturing and controls (CMC) and analytical activities required to advance the program.

The Series E-2 round received broad participation from Airway’s existing investor base, with approximately 94% of existing investors participating in the round. Participants included Cincinnati Children’s and a syndicate of large family offices, who are committed to advancing novel therapies for serious respiratory diseases.

“We are extremely pleased by the strong participation and continued support of our existing investors, with approximately 94% of our current cap table participating in the Series E-2 round, reflecting their confidence in Airway, our team and the potential of zelpultide alfa,” said Marc Salzberg, MD, Chairman and Chief Executive Officer of Airway Therapeutics. “With this round, we are well positioned to maintain momentum across our late-stage clinical program as we evaluate zelpultide alfa for the prevention of BPD in very preterm infants, a population with significant unmet medical need and no approved preventive therapies.”

“This round further solidifies Airway’s financial position as we execute the ongoing Phase 2b/3 clinical trial and prepare for the program’s next important development milestones,” said Alan S. Wolk, MBA, Chief Financial Officer and Chief Operating Officer of Airway Therapeutics. “The proceeds provide us with the capital to support the clinical study as well as the CMC and BLA readiness analytical work necessary to advance zelpultide alfa through late-stage development in a disciplined and efficient manner.”

Airway’s next major development milestone is the planned interim analysis marking the completion of the Phase 2b portion of the ongoing Phase 2b/3 clinical trial. Results from the interim analysis are expected by the end of the second quarter of 2027.

About Zelpultide Alfa
Zelpultide alfa is a recombinant human surfactant protein D (rhSP-D) precisely engineered to replicate the native protein’s full quaternary structure and biological function, incorporating optimized glycosylation through advanced cell line technology. Its therapeutic activity is driven by three key mechanisms: modulation of immune responses to mitigate excessive inflammation, enhancement of pathogen recognition and clearance, and maintenance of surfactant homeostasis to support pulmonary function. As a versatile biologic platform, zelpultide alfa is being developed for patients across all age groups—from preventing bronchopulmonary dysplasia (BPD) in very preterm infants to treating acute and chronic respiratory, inflammatory and infectious conditions in adults.

Zelpultide alfa’s lead indication, BPD prevention, is currently progressing through a Phase 2b/3 clinical trial, following a Phase 1b study that demonstrated a favorable safety and tolerability profile.

About Airway Therapeutics
Airway Therapeutics is a late-stage clinical biopharmaceutical company developing a new class of biologic therapies to redefine the prevention and treatment of respiratory, inflammatory, and infectious diseases. Its lead candidate, zelpultide alfa, is currently in late-stage clinical development for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants, a condition with no approved preventive therapies. As a platform biologic, zelpultide alfa is also being advanced for broader application across age groups and disease settings, with the goal of improving outcomes for vulnerable patient populations.

For more information, please visit https://www.airwaytherapeutics.com  

Company Contact:
Libba Muzi
Airway Therapeutics  
[email protected]
513-770-9630

SOURCE Airway Therapeutics

• Cette levée de fonds soutient l’essai clinique de phase 2b/3 en cours visant à prévenir la dysplasie bronchopulmonaire, ainsi que les activités associées en matière de CMC et d’analyse.
• Environ 94 % des investisseurs existants ont participé au tour de table de série E-2
• Une analyse intermédiaire clôturant la partie de phase 2b de l’essai est attendue d’ici la fin du deuxième trimestre 2027

ATLANTA, 25 août 2026 — Airway Therapeutics, Inc., une société biopharmaceutique spécialisée dans les essais cliniques de phase avancée et développant des traitements biologiques innovants pour les maladies respiratoires, inflammatoires et infectieuses, a annoncé aujourd’hui la clôture d’un tour de table de 50 millions de dollars destiné à soutenir la poursuite du développement clinique de phase avancée du zelpultide alfa, la nouvelle protéine D tensioactive humaine recombinante (rhSP-D) de la société.

Le tour de table « E » comprend 26 millions de dollars levés précédemment dans le cadre d’un financement SAFE et de 24 millions de dollars levés lors du tour de table de série E-2 de la société. Les fonds levés serviront principalement à permettre à Airway de mener à bien la partie « phase 2b » de l’essai clinique de phase 2b/3 en cours, qui évalue le zelpultide alfa dans la prévention de la dysplasie bronchopulmonaire (DBP) chez les prématurés extrêmes, ainsi que les activités de chimie, de fabrication et de contrôle (CMC) et les activités analytiques associées nécessaires à l’avancement du programme.

Le tour de table de série E-2 a bénéficié d’une large participation de la part des investisseurs actuels d’Airway, environ 94 % d’entre eux y ayant pris part. Parmi les participants figuraient le Cincinnati Children’s Hospital Medical Center et un consortium de grands family offices, qui se sont engagés à faire progresser des thérapies innovantes dans le cadre des maladies respiratoires graves.

« Nous sommes extrêmement satisfaits de la forte participation et du soutien continu de nos investisseurs existants, puisque près de 94 % des actionnaires figurant dans notre tableau de capitalisation actuel ont participé au tour de table de série E-2, ce qui témoigne de leur confiance en Airway, en notre équipe et dans le potentiel du zelpultide alfa », a déclaré le Dr Marc Salzberg, , président-directeur général d’Airway Therapeutics. « Grâce à cette levée de fonds, nous sommes bien placés pour maintenir notre élan dans l’ensemble de notre programme clinique de phase avancée, alors que nous évaluons le zelpultide alfa dans la prévention de la dysplasie bronchopulmonaire (DBP) chez les prématurés extrêmes, une population présentant un besoin médical non satisfait important et pour laquelle il n’existe aucun traitement préventif approuvé ».

« Ce tour de table renforce encore davantage la situation financière d’Airway à mesure que nous poursuivons l’essai clinique de phase 2b/3 en cours et que nous nous préparons à franchir les prochaines étapes importantes du programme », a déclaré Alan S. Wolk, MBA, directeur financier et directeur des opérations d’Airway Therapeutics. « Ces fonds nous apportent les ressources financières nécessaires pour financer l’étude clinique ainsi queles travaux d’analyse relatifs à l’activité CMC et à la préparation du dossier BLA (Biologics License Application), indispensables pour faire progresser le zelpultide alfa vers les phases avancées de développement de manière rigoureuse et efficace ».

La prochaine étape majeure du développement d’Airway est l’analyse intermédiaire prévue, qui marquera l’achèvement de la partie de phase 2b de l’essai clinique de phase 2b/3 actuellement en cours. Les résultats de l’analyse intermédiaire sont attendus d’ici la fin du deuxième trimestre 2027.

À propos du zelpultide alfa
Le zelpultide alfa est une protéine D tensioactive humaine recombinante (rhSP-D) conçue avec précision pour reproduire intégralement la structure quaternaire et la fonction biologique de la protéine native, et dont la glycosylation a été optimisée grâce à une technologie avancée de lignées cellulaires. Son activité thérapeutique repose sur trois mécanismes clés : la modulation des réponses immunitaires pour atténuer l’inflammation excessive, l’amélioration de la reconnaissance et de l’élimination des agents pathogènes et le maintien de l’homéostasie du surfactant pour soutenir la fonction pulmonaire. Plateforme biologique polyvalente, le zelpultide alfa est en cours de développement pour des patients de toutes les tranches d’âge, de la prévention de la dysplasie broncho-pulmonaire (DBP) chez les très grands prématurés au traitement des affections respiratoires, inflammatoires et infectieuses aiguës et chroniques chez l’adulte.

L’indication principale du zelpultide alfa, à savoir la prévention de la dysplasie bronchopulmonaire, fait actuellement l’objet d’un essai clinique de phase 2b/3, à la suite d’une étude de phase 1b qui a mis en évidence un profil de sécurité et de tolérance favorable.

À propos d’Airway Therapeutics
Airway Therapeutics est une société biopharmaceutique spécialisée dans les essais cliniques de phase avancée qui développe une nouvelle classe de traitements biologiques visant à redéfinir la prévention et le traitement des maladies respiratoires, inflammatoires et infectieuses. Son principal candidat, le zelpultide alfa, se trouve actuellement en phase avancée de développement clinique pour la prévention de la dysplasie bronchopulmonaire (DBP) chez les très grands prématurés, une affection pour laquelle il n’existe aucun traitement préventif approuvé. En tant que plateforme biologique, le zelpultide alfa fait également l’objet d’efforts d’application élargie à d’autres groupes d’âge et pathologies, en vue d’améliorer les résultats pour les populations de patients vulnérables.

Pour plus d’informations, rendez-vous sur https://www.airwaytherapeutics.com  

Contact de l’entreprise :
Libba Muzi
Airway Therapeutics  
[email protected]
513-770-9630